Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023
The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Themis will market this drug with the brand name REMITHEM.
Subscribe To Our Newsletter & Stay Updated